New Oral GLP-1 Drugs Offer Maintenance Option for Weight Loss After Injections

Introduction to Oral GLP-1 Options Eli Lilly launched its oral GLP-1 drug, sold as Foundayo, earlier this month.

The tablet is designed for weight maintenance after initial loss with injections like Zepbound. Novo Nordisk released oral Wegovy in December, which uses the same active ingredient as its injectable version. Oral Wegovy requires administration on an empty stomach with less than four ounces of water.

Both pills carry side effects including nausea and diarrhea, similar to the injections. Foundayo does not have specific timing restrictions for most users.

Clinical Evidence and Expert Views A clinical trial by Eli Lilly involving nearly 400 participants found that switching from Zepbound injections to Foundayo maintained most weight loss after 52 weeks.

The study results have not yet been published in a peer-reviewed journal. Novo Nordisk states that patients can switch from injectable Wegovy to the oral form without impacting weight maintenance, as both use semaglutide.

“— Andrea Traina, senior medical director for obesity at Novo Nordisk Initial reports from patients switching to oral Wegovy indicate positive outcomes, though long-term data are limited. Doctors note that older weight-loss pills have not been studied for GLP-1 maintenance, and reducing injection frequency lacks large-scale trial evidence.”

Practical Considerations and Costs Injections require weekly administration and refrigeration, which can complicate travel and adherence. Pills integrate into daily routines like other oral medications. A survey of employers shows that only about 20% of large company insurance plans cover GLP-1 drugs for weight loss. The lowest dose of Foundayo costs $149 per month out of pocket, half the price of Zepbound. Oral Wegovy starts at $149 monthly, compared to $199 for the injection. Medicare does not cover weight-loss drugs, though a pilot program under the Trump administration provides access for beneficiaries.

Research on Genetic Factors A Nature research paper identifies genetic predictors of weight loss and side effects from GLP-1 receptor agonists. The study analyzes how genetic variations influence responses to these drugs. Specific genes linked to efficacy and adverse reactions were detailed in the publication. Foundayo's non-peptide structure simplifies manufacturing, potentially lowering future costs. Patients may prefer pills for convenience, though some find weekly injections easier than daily dosing. Adherence varies based on individual needs and drug availability.

Broader Context GLP-1 drugs like Zepbound and Wegovy are used for long-term weight management after initial loss phases.

Weight regain occurs if treatment stops. Ongoing research explores more effective options, but maintenance strategies address adherence challenges.